Plasma-derived Factor VIII Market Size, Share, Growth, and Industry Analysis, By Types (200IU,250IU), By Applications (Hospital,Pharmacy) , and Regional Insights and Forecast to 2035

Plasma-derived Factor VIII Market Overview

Global Plasma-derived Factor VIII Market size is projected at USD 8761  million in 2026 and is expected to hit USD 14428.75 million by 2035 with a CAGR of 5.7%.

The Plasma-derived Factor VIII Market is a critical segment of the global hemophilia treatment ecosystem, driven by the increasing prevalence of hemophilia A and the continuous demand for plasma-based clotting factor therapies. Plasma-derived factor VIII products are obtained from human plasma and are widely used in prophylactic and on-demand treatment of bleeding disorders. The Plasma-derived Factor VIII Market Report indicates rising clinical utilization across hospitals and specialty treatment centers, supported by expanding plasma collection infrastructure and advanced purification technologies. Globally, more than 400,000 individuals are estimated to suffer from hemophilia, with hemophilia A accounting for nearly 80–85% of cases, driving strong demand for plasma-derived therapies. 

The United States represents one of the largest regional segments within the Plasma-derived Factor VIII Market Outlook due to a high concentration of hemophilia treatment centers and advanced healthcare infrastructure. More than 33,000 individuals in the United States are estimated to live with hemophilia, with hemophilia A representing the majority of diagnosed cases. The country maintains over 130 specialized hemophilia treatment centers, which play a significant role in the distribution and clinical administration of plasma-derived clotting factor products. The U.S. healthcare system performs thousands of prophylactic infusion treatments annually for hemophilia management, supporting steady demand for plasma-derived factor VIII products. 

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 80%–85% of hemophilia cases are hemophilia A requiring factor VIII therapy, while nearly 60% of diagnosed patients rely on plasma-derived factor concentrates and over 70% of severe cases require lifelong prophylactic infusions.
• Major Market Restraint: Around 20%–30% of hemophilia A patients develop inhibitors to factor VIII therapies, while 35% of healthcare providers report treatment cost barriers and nearly 25% of emerging markets experience plasma supply shortages.
• Emerging Trends: Approximately 45% of hemophilia treatment protocols now include long-acting factor concentrates, while 30% of treatment centers integrate personalized prophylaxis dosing and nearly 50% of pharmaceutical R&D investment targets advanced clotting factor formulations.
• Regional Leadership: North America accounts for nearly 40%–45% of the global Plasma-derived Factor VIII Market Share, while Europe represents around 30% and Asia-Pacific contributes nearly 20% of total plasma-derived clotting factor demand.
• Competitive Landscape: The top 10 manufacturers control approximately 65%–70% of the Plasma-derived Factor VIII Market Share, while tier-2 and regional manufacturers collectively contribute nearly 30%–35% of total plasma fractionation capacity.
• Market Segmentation: Hemophilia A treatment represents nearly 75%–80% of total product demand, surgical applications contribute around 10%–12%, trauma treatment accounts for roughly 5%–7%, and other therapeutic uses represent about 3%–5%.
• Recent Development: More than 40% of clinical trials in bleeding disorders focus on advanced factor therapies, while nearly 25% of biopharmaceutical investments are directed toward improved plasma purification and high-purity clotting factor concentrates.

Plasma-derived Factor VIII Market Latest Trends

The Plasma-derived Factor VIII Market Trends are evolving rapidly as healthcare providers increase the adoption of plasma-derived therapies for long-term hemophilia management. Hospitals and hemophilia treatment centers are expanding prophylactic treatment programs, which require regular infusions of factor VIII concentrates to prevent bleeding episodes. Approximately 70% of patients with severe hemophilia A require routine prophylaxis therapy, significantly increasing the consumption of plasma-derived clotting factors. 

Another important trend shaping the Plasma-derived Factor VIII Market Growth is the advancement of plasma fractionation technology. Modern purification techniques allow manufacturers to extract higher yields of factor VIII from donated plasma while maintaining improved safety standards. Plasma fractionation facilities process millions of liters of plasma annually to meet global therapeutic demand. Additionally, healthcare providers are increasingly integrating personalized dosing strategies, where treatment regimens are adjusted according to patient weight, bleeding frequency, and pharmacokinetic profiles. \

Plasma-derived Factor VIII Market Dynamics

DRIVER

"Increasing prevalence of hemophilia A worldwide"

The primary growth driver in the Plasma-derived Factor VIII Market Analysis is the increasing prevalence and diagnosis of hemophilia A globally. Hemophilia affects more than 400,000 individuals worldwide, with hemophilia A accounting for approximately 80–85% of cases. Treatment guidelines recommend regular prophylactic infusion therapy to prevent joint damage and life-threatening bleeding events. Severe hemophilia patients may require clotting factor therapy two to three times per week, resulting in high product consumption. In addition, improvements in newborn screening programs and genetic testing have significantly increased diagnosis rates in developing regions. 

RESTRAINTS

"Limited plasma supply and high treatment costs"

Despite strong demand, the Plasma-derived Factor VIII Market Insights reveal significant limitations related to plasma supply availability and production complexity. Plasma-derived clotting factors require large volumes of human plasma collected through donation programs. Manufacturing facilities must process thousands of plasma units to produce a limited quantity of factor VIII concentrate. The collection, storage, testing, and fractionation processes significantly increase production costs. In many developing regions, limited plasma donation infrastructure restricts access to adequate supply, creating treatment gaps. Additionally, long-term prophylactic therapy requires frequent infusions, increasing treatment expenses for healthcare providers and patients. 

OPPORTUNITY

"Expansion of plasma fractionation and global treatment access"

Expanding plasma fractionation capacity presents significant opportunities within the Plasma-derived Factor VIII Market Forecast. Pharmaceutical companies are investing heavily in new plasma processing facilities and advanced purification technologies to improve production efficiency. Global plasma collection networks have expanded significantly in the past decade, with hundreds of donation centers supporting the increasing need for clotting factor therapies. Governments and healthcare organizations are also increasing funding for hemophilia treatment programs in developing regions, improving patient access to factor VIII therapy. 

CHALLENGE

"Competition from recombinant and gene therapies"

One of the major challenges impacting the Plasma-derived Factor VIII Market Outlook is the rapid development of recombinant clotting factors and emerging gene therapies. Recombinant factor VIII therapies, produced using biotechnology rather than human plasma, are increasingly used due to consistent supply and reduced risk of blood-borne pathogen transmission. Biotechnology companies are also developing gene therapy treatments designed to provide long-term or potentially curative solutions for hemophilia patients. Clinical advancements in these innovative therapies are attracting substantial pharmaceutical investment and healthcare attention.

Plasma-derived Factor VIII Market Segmentation

The Plasma-derived Factor VIII Market Segmentation is categorized by type and application, reflecting variations in dosage strength and end-user distribution channels. By type, the market includes 200IU and 250IU formulations, widely utilized in hemophilia A prophylaxis and bleeding episode management. These dosage strengths support flexible treatment protocols based on patient body weight, severity of deficiency, and clinical requirements. By application, hospitals and pharmacies represent the primary distribution points for plasma-derived factor VIII therapies. Hospitals account for a significant portion of infusion treatments due to specialized hemophilia treatment centers and surgical interventions.

Download Free Sample to learn more about this report.

BY TYPE

200IU: The 200IU dosage segment represents a significant portion of the Plasma-derived Factor VIII Market Analysis due to its suitability for individualized dosing protocols and frequent prophylactic treatments. Hemophilia A patients require factor VIII replacement therapy to maintain clotting factor activity levels above 1% of normal plasma concentration, which is the threshold required to prevent spontaneous bleeding. The 200IU formulation is widely used in pediatric treatment regimens and weight-adjusted dosing strategies, particularly in patients requiring smaller infusion volumes. Approximately 50% of prophylactic therapy regimens involve variable dosing structures, where lower-strength formulations such as 200IU are combined to achieve patient-specific factor levels. Globally, hemophilia A accounts for nearly 80–85% of all hemophilia diagnoses, and around 60% of patients suffer from severe forms of the disorder, requiring regular prophylactic treatment several times per week. 

250IU: The 250IU segment plays a critical role in the Plasma-derived Factor VIII Market Size due to its widespread use in standard prophylaxis regimens and adult hemophilia treatment protocols. Factor VIII concentrates in the 250IU dosage category are commonly administered to maintain therapeutic clotting activity levels in moderate and severe hemophilia A patients. Clinical treatment guidelines indicate that maintaining clotting factor activity above 3–5% significantly reduces the risk of spontaneous joint bleeding, while activity levels above 10% can prevent many trauma-related bleeding events. Adult hemophilia patients often require larger infusion doses due to higher body weight and increased metabolic clearance of clotting factors. In many cases, dosing requirements range between 25 and 50 IU per kilogram body weight depending on bleeding severity and treatment strategy. The 250IU dosage format allows healthcare providers to administer therapeutic doses efficiently while minimizing infusion preparation time.

BY APPLICATION

Hospital: Hospitals represent one of the most significant application segments in the Plasma-derived Factor VIII Market Share because severe hemophilia cases and acute bleeding episodes require specialized clinical management. Globally, more than 400,000 individuals live with hemophilia, and approximately 60% of these patients experience severe clotting factor deficiency. Severe hemophilia patients frequently require immediate intravenous infusion therapy in hospital settings, particularly during trauma events, surgical procedures, or life-threatening bleeding complications. Hemophilia treatment centers located within hospitals play a crucial role in providing comprehensive care that includes diagnostic testing, prophylactic infusion programs, joint damage monitoring, and emergency bleeding management. More than 130 specialized hemophilia treatment centers operate across the United States alone, providing coordinated care for thousands of patients annually. 

Pharmacy: Pharmacies represent another major distribution channel within the Plasma-derived Factor VIII Market Growth, particularly for outpatient prophylactic therapy and long-term hemophilia management. Many hemophilia patients receive regular clotting factor infusions at home following physician guidance, making pharmacy-based supply systems essential for treatment continuity. Studies indicate that more than 70% of patients with severe hemophilia A rely on routine prophylaxis therapy, which often involves multiple infusions per week. Specialty pharmacies and hospital outpatient pharmacies distribute clotting factor concentrates directly to patients enrolled in chronic treatment programs. These pharmacies maintain temperature-controlled storage systems and regulated distribution channels to ensure product stability and safety. Home infusion therapy programs supported by pharmacies allow patients to administer clotting factor treatment without frequent hospital visits, significantly improving quality of life and treatment adherence. 

Plasma-derived Factor VIII Market Regional Outlook

The Plasma-derived Factor VIII Market Regional Outlook demonstrates strong geographical distribution driven by hemophilia prevalence, healthcare infrastructure, plasma collection capacity, and treatment accessibility. North America accounts for nearly 42% of the global Plasma-derived Factor VIII Market Share due to advanced treatment centers and high diagnosis rates. Europe contributes approximately 30% of the market, supported by strong rare disease treatment programs and plasma fractionation facilities. Asia-Pacific represents nearly 20% of the global market share as hemophilia diagnosis rates improve and healthcare investments expand across large population bases. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America holds the dominant position in the Plasma-derived Factor VIII Market Share with approximately 42% of global demand, supported by advanced healthcare infrastructure, strong plasma collection systems, and widespread hemophilia treatment programs. The region maintains one of the highest hemophilia diagnosis rates globally due to strong medical screening systems and specialized treatment centers. More than 33,000 individuals in the United States are living with hemophilia, with hemophilia A representing nearly 80–85% of total cases requiring factor VIII therapy. The region operates one of the largest plasma collection networks worldwide, with hundreds of plasma donation centers supporting the production of clotting factor concentrates. Plasma fractionation facilities across North America process millions of liters of plasma annually to meet both domestic and global demand for plasma-derived therapies. Advanced purification and virus inactivation technologies used in the region ensure high safety standards for plasma-derived factor VIII products. 

EUROPE

Europe represents approximately 30% of the global Plasma-derived Factor VIII Market Share and remains one of the most established regions for hemophilia treatment and plasma-derived therapeutics. The region benefits from well-developed healthcare systems, government-funded rare disease programs, and strong collaboration between hemophilia treatment centers and pharmaceutical manufacturers. Across Europe, more than 100,000 individuals are estimated to live with hemophilia and related bleeding disorders, with hemophilia A accounting for the majority of diagnosed cases requiring factor VIII replacement therapy. European healthcare systems emphasize early diagnosis and long-term prophylactic treatment. Many countries within the region have national hemophilia registries that track patient outcomes and treatment utilization. These registries support clinical monitoring and help ensure consistent access to clotting factor therapy. Prophylaxis treatment programs have significantly reduced the frequency of joint bleeding episodes among patients receiving regular factor VIII infusions. 

GERMANY Plasma-derived Factor VIII Market

Germany represents one of the most advanced national markets within the European Plasma-derived Factor VIII Market Share, contributing approximately 7% of the global market demand. The country maintains a well-developed healthcare infrastructure and strong rare disease treatment programs that support early diagnosis and continuous management of hemophilia patients. Germany operates numerous specialized hemophilia treatment centers that provide comprehensive care including clotting factor infusion therapy, diagnostic testing, and long-term patient monitoring. The country maintains strong plasma collection programs that support the manufacturing of plasma-derived therapies. German plasma donation centers collect large volumes of plasma annually under strict regulatory supervision to ensure high product safety standards. These donation programs supply plasma fractionation facilities responsible for producing clotting factor concentrates used both domestically and across international markets. Hemophilia treatment in Germany emphasizes prophylaxis therapy, particularly for patients with severe clotting factor deficiency. 

UNITED KINGDOM Plasma-derived Factor VIII Market

The United Kingdom accounts for approximately 5% of the global Plasma-derived Factor VIII Market Share and maintains a structured national approach to hemophilia treatment and rare disease management. The country has an estimated 8,000 individuals living with hemophilia, with hemophilia A representing the majority of cases requiring clotting factor therapy. National healthcare programs provide comprehensive treatment coverage through specialized hemophilia centers distributed across major hospitals. These treatment centers coordinate patient diagnosis, prophylaxis therapy, and long-term clinical monitoring. Severe hemophilia patients in the United Kingdom often receive regular clotting factor infusions to prevent spontaneous bleeding episodes and long-term joint damage. National treatment guidelines recommend early prophylaxis therapy beginning in childhood, significantly improving patient outcomes and life expectancy. 

ASIA-PACIFIC

Asia-Pacific accounts for approximately 20% of the global Plasma-derived Factor VIII Market Share and represents one of the fastest expanding regions for hemophilia diagnosis and treatment access. The region contains a large population base, which contributes to a substantial number of individuals living with hemophilia and other bleeding disorders. However, diagnosis rates historically remained lower than those in North America and Europe due to limited healthcare access and awareness in certain countries. In recent years, governments across Asia-Pacific have expanded rare disease programs and improved diagnostic capabilities. National healthcare systems are investing in hemophilia treatment centers, laboratory testing facilities, and patient registries to improve disease detection. As a result, the number of diagnosed hemophilia patients has increased significantly across several countries. Healthcare infrastructure improvements have also expanded access to clotting factor therapy. Hospitals in major urban centers now provide regular prophylactic infusion programs for patients with severe hemophilia. 

JAPAN Plasma-derived Factor VIII Market

Japan represents a technologically advanced market within the Asia-Pacific Plasma-derived Factor VIII Market Share and contributes approximately 6% of global demand. The country maintains a well-organized healthcare system with strong rare disease management programs and comprehensive hemophilia treatment services. Japan has an estimated 6,000 to 7,000 individuals living with hemophilia, with hemophilia A representing the majority of cases requiring factor VIII therapy. Japanese healthcare providers emphasize early diagnosis and continuous prophylaxis therapy. Patients with severe hemophilia frequently receive scheduled infusion therapy to maintain clotting factor activity levels sufficient to prevent spontaneous bleeding. Many treatment centers use advanced pharmacokinetic monitoring techniques to determine optimal dosing schedules for individual patients. The country also maintains strict plasma safety standards supported by advanced testing and purification technologies. Plasma donation programs operate under highly regulated frameworks that ensure donor safety and product quality. 

CHINA Plasma-derived Factor VIII Market

China represents one of the largest patient populations within the Asia-Pacific Plasma-derived Factor VIII Market Share and contributes approximately 8% of global demand. Due to its large population, China has a significant number of individuals affected by hemophilia, although diagnosis rates historically remained lower compared with Western countries. Increased healthcare investment and national rare disease initiatives have significantly improved hemophilia detection and treatment access. Government healthcare programs have expanded the number of hemophilia treatment centers across major cities. These centers provide diagnostic testing, prophylactic infusion therapy, and long-term patient monitoring. Improved awareness among healthcare providers and patients has resulted in increased diagnosis rates and better disease management. China has also expanded domestic plasma collection and fractionation capacity to support the production of plasma-derived therapeutic products. Plasma donation programs operate across several provinces, supplying plasma fractionation facilities responsible for manufacturing clotting factor concentrates used within the national healthcare system. 

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 8% of the global Plasma-derived Factor VIII Market Share and represents an emerging market for hemophilia treatment and plasma-derived therapeutics. The region has historically experienced limited access to specialized hemophilia care due to constrained healthcare infrastructure and limited diagnostic resources. However, recent healthcare investments and international partnerships have significantly improved treatment accessibility. Several countries in the Middle East have established specialized hemophilia treatment centers within major hospitals. These centers provide diagnostic testing, prophylactic therapy programs, and emergency bleeding management for patients with clotting disorders. National healthcare authorities have also implemented rare disease awareness initiatives to improve diagnosis rates and encourage early treatment. Plasma-derived clotting factor therapy remains an essential component of hemophilia treatment in the region, particularly in hospital settings where patients receive supervised infusion therapy. Severe hemophilia patients often require multiple infusion treatments each month to maintain adequate clotting factor activity levels and prevent spontaneous bleeding episodes. In Africa, international health organizations and humanitarian programs have supported the distribution of clotting factor concentrates to underserved populations. These initiatives aim to improve survival rates and quality of life for patients living with hemophilia. Training programs for healthcare providers also help improve diagnosis and clinical management of bleeding disorders. With expanding healthcare infrastructure, increasing government investment, and growing awareness of rare diseases, the Middle East & Africa region continues to gradually strengthen its role in the Plasma-derived Factor VIII Market Opportunities and contribute to global treatment accessibility.

List of Key Plasma-derived Factor VIII Market Companies

• Takeda
• Octapharma
• CSL
• Grifols
• Greencross
• Kedrion
• BPL
• Hualan Bio
• RAAS

Top Two Companies with Highest Share

• Takeda: holds approximately 21% of the global Plasma-derived Factor VIII Market Share supported by extensive plasma fractionation capacity, global hemophilia treatment distribution networks, and large-scale plasma collection infrastructure.
• CSL: accounts for nearly 18% of the global Plasma-derived Factor VIII Market Share driven by strong biotechnology manufacturing capabilities, advanced purification technology, and an extensive international plasma donation network.

Investment Analysis and Opportunities

Investment activity within the Plasma-derived Factor VIII Market Analysis continues to expand as pharmaceutical companies strengthen plasma collection infrastructure and develop advanced plasma fractionation technologies. Approximately 45% of global plasma therapy investments are directed toward expanding plasma donation centers, improving supply chain stability for clotting factor production. Around 35% of biopharmaceutical investment programs are focused on improving purification and viral inactivation technologies to enhance product safety and quality. Plasma-derived therapies remain essential for hemophilia treatment because nearly 80–85% of diagnosed hemophilia cases involve factor VIII deficiency, creating consistent demand for clotting factor concentrates. Global healthcare systems are also allocating approximately 30% of rare disease treatment budgets to hemophilia management programs, supporting expanded procurement of clotting factor therapies.

Significant investment opportunities are emerging in developing regions where hemophilia diagnosis rates are increasing rapidly. In several emerging markets, diagnosis rates have improved by nearly 25% following national rare disease awareness programs. Healthcare infrastructure investments are expanding hemophilia treatment centers, with approximately 40% of new specialized centers established within the last decade. Pharmaceutical manufacturers are also increasing capacity for plasma fractionation, with production efficiency improvements reaching nearly 20% through modern processing technologies. In addition, about 50% of biotechnology partnerships focus on developing improved clotting factor formulations with enhanced stability and longer circulation time. These strategic investments are strengthening global supply chains and creating long-term Plasma-derived Factor VIII Market Opportunities for pharmaceutical companies and healthcare providers.

New Products Development

New product development within the Plasma-derived Factor VIII Market Trends focuses on improving clotting factor stability, purity, and therapeutic efficiency. Approximately 40% of pharmaceutical research programs targeting bleeding disorders are focused on optimizing plasma-derived clotting factor formulations. Manufacturers are implementing advanced purification techniques capable of removing more than 99% of plasma impurities while maintaining high therapeutic activity. Improvements in viral inactivation processes have increased product safety levels by nearly 95%, strengthening regulatory compliance and patient confidence in plasma-derived therapies. Additionally, about 30% of ongoing product development programs are exploring extended half-life factor concentrates designed to reduce infusion frequency for hemophilia patients.

Manufacturers are also integrating advanced filtration technologies and chromatographic purification methods to improve yield efficiency during plasma fractionation. These technologies have increased clotting factor extraction efficiency by nearly 15% compared with earlier production processes. Approximately 35% of biotechnology innovation programs now focus on improving storage stability, allowing plasma-derived products to maintain potency under controlled storage conditions for longer durations. Furthermore, clinical development programs are testing personalized dosing approaches that adjust infusion levels based on patient pharmacokinetic profiles. Around 45% of hemophilia treatment centers are participating in pharmacokinetic monitoring initiatives that support individualized therapy regimens. These innovations continue to shape the evolution of the Plasma-derived Factor VIII Market Outlook.

Five Recent Developments

• Takeda: In 2024, the company expanded its global plasma collection network by increasing plasma donation capacity by approximately 18%, strengthening supply availability for plasma-derived therapies and improving distribution efficiency across more than 60% of its global treatment network.
• CSL: In 2024, CSL enhanced its plasma fractionation production efficiency by nearly 15% through upgraded purification systems, improving clotting factor extraction yield while maintaining viral inactivation safety levels exceeding 99% for plasma-derived therapeutics.
• Grifols: In 2024, the manufacturer introduced upgraded plasma processing technology that improved purification accuracy by approximately 20%, enabling higher recovery rates of factor VIII protein during fractionation and supporting broader therapeutic availability.
• Octapharma: In 2024, the company increased global distribution capacity by nearly 22% by expanding partnerships with hemophilia treatment centers and hospital networks, strengthening access to plasma-derived clotting factor therapy across multiple healthcare regions.
• Kedrion: In 2024, the manufacturer strengthened its plasma donor recruitment programs, achieving a 17% increase in plasma collection volumes, helping support expanded production of clotting factor concentrates used in hemophilia treatment programs.

Report Coverage Of Plasma-derived Factor VIII Market

The Plasma-derived Factor VIII Market Report provides comprehensive insights into the global therapeutic landscape for clotting factor replacement therapies used in hemophilia treatment. The report analyzes key factors influencing market expansion including increasing diagnosis rates, improvements in plasma fractionation technology, and rising adoption of prophylaxis therapy. Approximately 80–85% of hemophilia patients require factor VIII replacement therapy, while nearly 60% of diagnosed individuals experience severe clotting factor deficiency requiring regular infusion treatment. The report evaluates market segmentation across dosage types and clinical application channels, highlighting the importance of hospital treatment centers and pharmacy-based distribution systems in ensuring consistent patient access to clotting factor therapy.

The Plasma-derived Factor VIII Market Research Report also provides detailed regional insights covering North America, Europe, Asia-Pacific, and Middle East & Africa. North America contributes roughly 42% of global market share, while Europe accounts for nearly 30% of the overall treatment demand. Asia-Pacific represents approximately 20% of global consumption as diagnosis rates and healthcare investments expand across large population bases. The report also examines competitive market structure, where the top ten manufacturers collectively account for nearly 70% of total global plasma-derived clotting factor production capacity. Additionally, the study analyzes investment trends, technological advancements, plasma collection infrastructure development, and product innovation strategies shaping the future of the Plasma-derived Factor VIII Market Outlook.